Pipeline Expansion Zealand Pharma has a robust pipeline with ten drug candidates in clinical development, of which two are already on the market. This indicates ongoing growth and a need for innovative support tools, partnerships, and technologies that can accelerate drug development and commercialization processes.

Strategic Collaborations The company's recent multi-program collaboration with OTR Therapeutics and their strategic focus on metabolic diseases present opportunities to offer specialized R&D solutions, licensing arrangements, or co-development platforms tailored to metabolic health innovations.

Focus on Obesity Markets Zealand Pharma’s leading obesity programs, backed by major partners like Roche and Boehringer Ingelheim, point to a significant market segment. Sales efforts can target advanced therapeutics, bioprocessing tools, or biopharmaceutical manufacturing solutions aligned with obesity treatment.

Financial Investment & Growth With revenue estimated between $25 million and $50 million and recent significant asset sale to Roche for $5.3 billion, Zealand Pharma demonstrates healthy financial activity and strategic liquidity, opening potential for partnership opportunities, and innovative investment products or joint ventures.

Leadership and Innovation The appointment of new C-level executives like the Chief Scientific Officer and Chief Development Officer highlights a strong focus on scientific innovation and operational leadership, signaling opportunities for consultancy, executive training services, or advanced scientific tools to support their R&D efforts.